Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q1FY24 of ₹6,851.00 Crores up from ₹6,236.00 Crore year on year, a rise of 9.86%.
Total Expenses for Q1FY24 of ₹6,086.00 Crores up from ₹5,598.00 Crores year on year, a rise of 8.72%.
Consolidated Net Profit of ₹570.00 Crores up 9.62% from ₹520.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.74, up 9.68% from ₹8.88 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.